VYNT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Dec 2023 @ 15:39):

Stats
Today's Volume	19 116.00
Average Volume	17 863.00
Market Cap	1.23M
EPS	$0 ( 2024-03-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0721
ATR14	$0.00900 (4.64%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Hansen Paul R.	Buy	6 783	Common Stock, $0.0001 par value
2023-01-17	Hansen Paul R.	Buy	4 032	Common Stock, $0.0001 par value
2023-01-17	Harris Geoffrey E.	Buy	5 712	Common Stock, $0.0001 par value
2023-01-17	Fletcher R John	Buy	4 368	Common Stock, $0.0001 par value
2023-01-17	Horobin Joanna	Buy	7 526	Common Stock, $0.0001 par value

INSIDER POWER
98.23
Last 98 transactions
Buy: 5 441 265 \| Sell: 193 337

Volume Correlation

Long: -0.14 (neutral)

Short: 0.17 (neutral)

Signal:(69.635) Neutral

Cancer Genetics Inc Correlation

10 Most Positive Correlations
BOCH	0.893
SHSP	0.855

10 Most Negative Correlations
TDAC	-0.958
GAINL	-0.9
APOP	-0.882
RMRM	-0.838
NTEC	-0.825
ISNS	-0.814
CMLF	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cancer Genetics Inc Correlation - Currency/Commodity

-0.24
( neutral )

-0.28
( neutral )

0.00
( neutral )

-0.14
( neutral )

-0.64
( weak negative )

0.26
( neutral )

Cancer Genetics Inc Financials

Annual	2022
Revenue:	$666 000
Gross Profit:	$-342 000 (-51.35 %)
EPS:	$-3.87

Q4	2022
Revenue:	$46 000.00
Gross Profit:	$-15 000.00 (-32.61 %)
EPS:	$-1.760

Q3	2022
Revenue:	$152 000
Gross Profit:	$-105 000 (-69.08 %)
EPS:	$-0.580

Q2	2022
Revenue:	$165 000
Gross Profit:	$-139 000 (-84.24 %)
EPS:	$-0.980

Financial Reports:

No articles found.

Cancer Genetics Inc

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.